CMA proposes updated guidance on unfair contract terms to reflect current market practices and digitalization
The Competition and Markets Authority (CMA) published draft revised guidance (CMA37) intended to replace existing standards for businesses on unfair contract terms under the Consumer Rights Act 2015. This update reflects evolving case law and modern digital business models, aiming to clarify how terms governing subscriptions, data usage, and price increases are evaluated for fairness. It signals a heightened enforcement focus on transparency and the balance of rights between firms and consumers.
Telemetry is advisory — directional context, not a deterministic risk score.
Strategic Governance Impact
Structural governance significance — not general importance.
Important development
The UK Competition and Markets Authority's proposed updated guidance clarifies how existing consumer protection law applies to modern digital business models, particularly subscription services and data usage. This represents an incremental update to regulatory interpretation rather than a new legislative mandate or structural governance framework. While B2C organisations must review their standard contract terms to align with these clarified expectations, the development does not alter fundamental corporate governance requirements.
Exposure pathway
B2C firms, legal departments, and compliance officers are exposed as the updated guidance will form the basis for CMA enforcement actions and court interpretations. Subscription-based services and digital platforms are particularly vulnerable to challenges regarding complex termination or price-adjustment clauses.
What may need to be proven
Firms will need to document the 'fairness' rationale for standard terms, including evidence of how terms were negotiated or presented to ensure they do not create a significant imbalance. Legal teams must prepare to audit existing boilerplate contracts against the new illustrative examples of unfairness provided in the guidance.
Operational consequence mapping
What this signal actually changes
- What operational condition changed?
- The threshold for transparency and 'good faith' in consumer contracts is being recalibrated to account for digital-first interactions.
Consequence analysis · premium
Full operational consequence mapping — actors exposed, broken assumptions, evidence expectations, operational burden — is reserved for Premium and Executive subscribers.
Request accessSource citation
UK GOV.UK Policy Papers
GRandCIndex monitors source publications without reproducing them verbatim. Original materials remain the authoritative reference.
Executive interpretation · premium
Premium subscribers receive structured interpretation: cross-jurisdictional read-across, board-level translation, and proof-exposure mapping linked to internal control taxonomy.
Request accessConvergent signals
Reinforcing pressure across different stories
- High2026-08-19US#consumer-protection#junk-fees#ftc-enforcement#deceptive-pricingSIG-2026-5FNMQTStrongEscalatingImmediateLegal
FTC and Connecticut Secure $4 Million Settlement Over Deceptive Junk Fees and Add-on Charges
The Federal Trade Commission and the Office of the Attorney General of Connecticut finalized a $4 million settlement with an automotive dealership group for systemic deceptive pricing practices. The action addresses the illegal use of 'junk fees,' including double-charging for vehicle certifications and imposing non-consensual add-on products on consumers.
+5 more reinforcing signals · premium
Pattern context
Related signals in the same risk surface
- Medium2026-08-25US#fda-authorization#medical-devices#digital-health#wearable-techSIG-2026-1HWYI5StrongEscalatingImmediateEngineering
FDA Authorizes First Wearable Dual Glucose and Ketone Continuous Monitoring System
The U.S. Food and Drug Administration (FDA) authorized the marketing of the Libre Duo 10 Day Continuous Dual Glucose-Ketone Monitoring System, the first wearable device capable of simultaneous, continuous tracking of both metrics. This de novo authorization establishes a new regulatory precedent for integrated metabolic monitoring devices intended for individuals aged two and older with diabetes.
+3 more related signals · premium